return equiti ttm
wednesday morn abbott post anoth strong quarter support thesi
center consist organ sale growth peer earn growth low
doubl digit least new product momentum opportun varieti segment
financi flexibl
report revenu billion roughli line street estim
though impact larger-than-initially-expect foreign currenc headwind
compar oper basi revenu growth constant-curr basi
point better model growth strength exhibit across busi
segment though note standout perform medic devic constant
current quarter includ diabet led freestyl libr structur heart led
mitraclip diagnost led continu global roll-out alin momentum
product line may pick traction next month new
reimburs approv manufactur capac expans next-gener version
earn perspect ep grew came model
expect continu focu deliv approxim basi point annual
oper margin improvementslarg corpor effici sale growth
double-digit ep growth even invest intern product line expect
drive consist sale growth medic devic peer throughout come quarter
concurr today result abbott rais guidanc call
oper revenu growth expect neg currenc impact
prior rang adjust ep expect rang
nearli midpoint previous third
quarter compani anticip oper revenu growth rang
neg currenc impact roughli adjust ep rang
addit compani fundament strength abbott cash balanc continu grow
rais question around manag deploy asset near
term answer remain primarili around manufactur capac pay debt
drive market awar said debt/ebitda expect reach
year-end believ manag look aggress optionsshar
repurchas desir seem low call increas dividend much would move
needl medic devic establish pharmaceut like
categori also one higher valuat
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
stock thought conclus
look forward next month believ end-market demand remain robust across
segment margin expans play pipelin new product launch continu gain traction back
substanti invest cash flow creat accret opportun believ support current multipl
time forward ep room upsid result number lever compani avail rate abbott
diabet diabet one highlight quarter driven continu strength adopt freestyl
libr fgm system libr highlight includ global sale million year-over-year doubl digit
sequenti privat pharmaci coverag type type live unit state last
quarter latter driven primarili two new major payer decis sum perform quarter continu
deliv upsid expect continu momentum libr result organ growth full-year
notabl manag reiter confid gain fda approv libr icgm design though stop
short provid clariti time reason approv process take longer least street believ would
said base data present earlier year believ product come market year
manag also provid commentari abil use libr platform target type diseas state
outsid diabet time could provid leg growth stori believ larg earli
stage like sever year away could put busi path billion billion sale billion
libr remind libr similar function origin libr add option real-tim alarm
high/low glucos level call manag reiter confid receiv icgm approv libr
 stop short provid firm timelin approv launch street
seemingli expect icgm approv occur second-quart call manag note libr icgm
approv still within intern timelin continu expect near-term approv product
recal year ada meet abbot present data new algorithm libr sensor show
improv accuraci mean absolut rel deviat mard compar previous
new algorithm appear improv sensor accuraci low rang someth histor
struggl ultim reinforc confid libr receiv icgm approv said
remind investor manag temper expect libr acceler adopt given
compani focu flash monitor real-tim alert someth origin libr alreadi well suit
suppli chain invest abbott continu heavili invest manufactur capac libr sensor
expect throughput meaning expand second half first wave capac expans
come line next coupl month user growth impress freestyl libr continu
suppli constrain though backord expect abbott increas sales-and-market
educ expens drive demand exist new market libr nice-to-hav product
launch believ capac increas come could bigger impact result
basi point sequenti approxim million ahead estim strength quarter attribut
continu momentum mitraclip sale global led exist account bolster earli
benefit expand indic treat secondari mitral regurgit mr
said abbott still need secur reimburs treatment secondari mr sale potenti
sustain acceler recal abbott file reimburs approv first-quart call guid
reimburs approv year-end earli believ overwhelmingli posit result coapt trial
support posit reimburs decis manag note sever privat payer alreadi updat
polici conserv model meaning sale acceler get detail
abbott highlight recent fda approv fourth-gener mitraclip system offer wider rang clip
size enhanc placement featur like new leaflet grasp real-tim left atrial pressur monitor help
assess mr reduct intra-op second-quart call abbott start control roll-out new
system plan enter broad launch toward end overal remain posit durabl
mitraclip sale abbott make headway larg undertr mr opportun low-singl digit penetr
 market patient expect coapt trial coupl new system help increas
surgeon convers util product
neuromodul world-wide neuromodul sale includ drg db constant currenc
quarter intern sale compani express improv sequenti basi
sale constant currenc first quarter includ though busi remain
market growth overal compani growth
compani attribut weak two primari area right size sale organ lack new
technologies/product drive demand marketplac believ least manag control
drive improv second half year abbott complet intend salesforc expans
focus product gain howev note given time hire trial implant perman implant
rep may requir long month becom fulli product believ busi continu take
time recov
capit alloc manag reiter feel comfort capit posit strateg flexibl
compani continu pay debt go roughli million debt repurchas last two year
billion repurchas million first quarter expect debt/ebitda ratio reach time year-
end compar time end time follow close st jude acquisit earli
allow financi flexibl
beyond debt pay believ compani continu particular order maintain dividend growth line
ep invest organ growth opportun includ manufactur capac pipelin product explor
opportun space note compani alreadi meaning rais dividend end last year
target zone net incom heavi near-term invest manufactur capac primarili diabet
diagnost may come time manag continu dissuad investor assum larger organ
share repurchas near term cash reserv model simpli expand
 commentari rel non-descript manag continu feel pressur aggress
acquir said still believ compani would aggress pursu right strateg financi transact
appear specif believ abbott sight set sever acquisit target medic devic
establish pharmaceut space readi make aggress move price right
manag histor savvi acquir pick asset face short-term pressur
attract portfolio synergist busi segment establish pharmaceut expect acquisit
would focus smaller privat compani would expand compani portfolio premium gener medic
devic believ host compani across spectrum market cap attract end-market
uniqu product offer could bolster abbott long-term organ growth profil continu think abbott financi
flexibl afford uniqu posit bolster product portfolio either tuck-in large-scal acquisit
diagnost organ fxn growth segment follow similar trend first quarter
largest subseg laboratori lead way organ fxn growth may nitpick
continu market growth molecular organ fxn intern point organ fxn
caus part ngo purchas patent africa overli concern main area
growth organ expect stabil head throughout focu
remain compani abil continu grow lab alin well abil stabil turn
around aler rapid diagnost new product introduct refresh well continu growth
infecti diseas test id platform cardio-metabol test grew quarter
relat alin strength product roll-out led lab growth fxn
intern primarili led on-going uptak product line immunoassay clinic chemistri platform europ
system put field manag remain extrem bullish model alin
note remain earli inning roll hematolog molecular diagnost offer product
famili manag told us molecular offer expect approv late mean segment
growth like come addit continu see custom retent gain
signific share win alin win signific amount competit bid manag previous told us
competit win around last month said call
move forward team intend round core menu approv requir acceler southeast asia adopt
mean anoth leg revenu infus could sustain growth lab busi high-single-digit rang
coupl year fact manag specif note alin roll-out driver growth next
year work replac instal base legaci platform competit win may go long due product cycl
eventu come other space given setup team deploy addit resourc build
capac fulli fund roll-out overal alin conced biggest bull street come
opportun given slow natur share win time menu buildout occur result shown
europ thu far roll-out begin southeast asia clear famili like continu
lead way growth highli profit segment abbott busi help continu close gap
guidanc manag updat sale guidanc rang organ constant-curr growth
previou growth reflect strong perform first half support
continuing/acceler momentum sever key busi segment
third quarter team expect sale growth approxim organ fxn basi busi line
manag expect mid- high-single-digit growth establish pharmaceut midsingle-digit growth nutrit
midsingle-digit growth diagnost high-singl digit legaci diagnost low-to-mid singl diagnost
high-single-digit growth medic devic support double-digit growth sever busi segment view guidanc
achiev beatabl potenti upsid driver stem new product introduct indic expans
name mitraclip libr alin platform
adjust earn per share third quarter expect rang reflect growth
midpoint
updat model follow quarterli result manag guidanc
sale increas sale estim billion reflect organ fxn growth report
growth
earn increas earn per share estim account slight beat
first quarter new estim reflect annual growth
sale slightli decreas sale estim billion reflect organ fxn growth
new estim essenti unchang previou estim
earn slightli increas earn per share estim impli year-over-year
growth new estim compar previou estim growth
